[1]. Kim W, Egan JM, The role of incretins in glucose homeostasis and diabetes treatment, Pharmacol Rev,60(4), 2008, 470-512.
[2]. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, BloomSR, The inhibitory effects of peripheral administration of peptide YY (3–36) and glucagonlikepeptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamicpathway, Brain Res,1044(1), 2005, 127-131.
[3]. Amiranoff B,Vauclin-Jacques N, Laburthe M, Interaction of gastric inhibitory polypeptide(GIP) with the insulin-secreting pancreatic beta cell line, In lll: characteristics of GIP bindingsites, LifeSci,36(9),1985,807-813.
[4]. Thulé PM, Mechanisms of current therapies for diabetes mellitus type 2, Advances in Physiology Education.,36(4), 2012, 275-283.
[5]. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U,Watanabe T, Drucker DJ, Wagtmann N, Enhanced insulin secretion and improved glucosetolerance in mice lacking CD26,PNAS; 97(12),2000,6874–6879.